Careers at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

5 organizations at ACT 2026 present work in careers: 4 drug developers and 1 service, testing or tools company. Between them they bring 15 presentations to the program. Most represented: Bristol Myers Squibb (5 on the program), Boehringer Ingelheim (4 on the program), Biologics Consulting (1 on the program). 2 of them have their own page in this guide. As of Oct 8, 2026.

All 231 organizations at ACT 2026 →

Showing 1–5 of 5 organizations

Organization	ACT 2026 Attendance
Bristol Myers Squibb
bms.com Pharmaceutical companies Global pharmaceutical company with marketed medicines in oncology, immunology, cardiovascular disease and neuroscience.	Talk Mon Nov 16 2:05pm–2:40pm Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) De-risking of Nonclinical Renal Safety Signals through Investigative Studies and Robust Clinical Monitoring (S06-2) Translational safety Poster Mon Nov 16 5:00pm–6:30pm Terminology Translation of SEND and MedDRA for Enabling Translational Safety: Challenges, Use Cases, and Collaborative Opportunities (P528) Nelson Exhibit Ballroom · Poster P528 Study data · Translational safety Poster Mon Nov 16 5:00pm–6:30pm Unlocking the Value of Shared Toxicology Data: How BioCelerate Members Use Historical Data to Support Preclinical Research (P445) Nelson Exhibit Ballroom · Poster P445 Study data Talk Tue Nov 17 2:05pm–2:40pm Part of Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline (S11) Introduction to the ICH Q3E Draft Guideline: Extractables & Leachables - A Pharmaceutical Industry Perspective (S11-2) Chemical risk assessment · Regulatory Session Wed Nov 18 2:00pm–3:15pm The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Careers · with BioMarin 2:00pmConventional and Unconventional Trajectories to a Toxicologist Career in the Pharmaceutical Sector (S16-1)Boehringer Ingelheim 2:20pmTransitioning from Government Regulator to the Private Sector (S16-2)BlueRock Therapeutics 2:40pmSo You Want to Be a Consultant? (S16-3)Biologics Consulting
Boehringer Ingelheim Ingelheim, Germany
boehringer-ingelheim.com Pharmaceutical companies Family-owned German pharmaceutical company developing human medicines and animal health products.	Session Sun Nov 15 8:00am–11:30am First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Translational safety · with Novartis 8:00amFoundational Approaches to FIH Dose Selection (CE1-1)White Oak Regulatory Tox 8:20amModel-Informed Approaches to FIH Dose Prediction (CE1-2)Bedard ADME-Tox Solutions, Tango Therapeutics 8:45amCNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)Akkeri 9:10amInter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)Novartis 10:00amCrossing the Species Divide in Inhaled Dosing (CE1-5)Novartis 10:25amInteractive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6)Boehringer Ingelheim Session Sun Nov 15 8:00am–11:30am From Predictive Models to Collaborative Intelligence: The Role of Agentic AI in the Future of Toxicology (CE2) In silico and AI · with Human Chemical 8:00amWelcome and Course Overview (CE2-1)Human Chemical 8:05amAgentic AI 101: A Primer for Drug Discovery and Development Toxicologists (CE2-2)Taiho Oncology 8:30amAgentic AI Frameworks for Predictive Toxicology-Based Literature Searches (CE2-3)Coincidence Labs 9:00amSynthesizing Experimental Results and In-Silico Predictions for Autonomous Hypothesis Generation (CE2-4)Human Chemical 10:00amLeveraging Agentic AI to Reassess and Optimize Previously Failed Compounds (CE2-5)Ignota Labs 10:30amChemistry Foundation Models for Optimal Drug Design (CE2-6)deepmirror Talk Sun Nov 15 10:25am–11:30am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Interactive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6) Translational safety Poster Mon Nov 16 5:00pm–6:30pm IL-10–Associated Thrombocytopenia Is Not Mediated by Direct Platelet Effects (P129) Nelson Exhibit Ballroom · Poster P129 Immunotoxicology · Pathology Poster Mon Nov 16 5:00pm–6:30pm Strengthening Regulatory Confidence in Liver MPS: Insights from The 3Rs Collaborative’s & FDA CDER’s Cross Platform DILI Project (P213) Nelson Exhibit Ballroom · Poster P213 New approach methods · Regulatory Session Tue Nov 17 9:00am–12:00pm Next-Generation Liver Toxicity Assessment: Integrating Human-Relevant NAMs, AI, and Exposure Modeling (S07) New approach methods · In silico and AI · with Physicians Committee for Responsible Medicine 9:00amIntroduction (S07-1)Physicians Committee for Responsible Medicine 9:05amAn Integrated NAM Platform Combining Bioactivity Prediction with PBPK and Literature Intelligence for Chemical Liver Toxicity Assessment (S07-2)Human Chemical 9:30amMulticellular Hepatic In Vitro Models Using NANOSTACKS™: Flow-Driven Differential Toxicity and Human-Relevant Drug Response Prediction (S07-3)Revivocell 9:55amAI-Enabled, Exposure-Anchored DILI Prediction Using Human 3D Liver Microtissues (S07-4)InSphero 10:45amFrom Exposure Dynamics to Uncertainty: A Hybrid Framework for Drug-Induced Liver Injury Prediction (S07-5)ESQlabs 11:25amNovel Optical Techniques to Study Hepatic Microplastic Pollution: Optical Imaging as a Powerful New Approach Methodology (S07-6)University of New Mexico Talk Wed Nov 18 2:00pm–2:20pm Part of The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Conventional and Unconventional Trajectories to a Toxicologist Career in the Pharmaceutical Sector (S16-1) Careers
Biologics Consulting Alexandria, VA
biologicsconsulting.com Consultancies Regulatory and product development consultancy for biologics, drugs and devices, with nonclinical pharmacology-toxicology, clinical and manufacturing support.	Talk Wed Nov 18 2:40pm–3:00pm Part of The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) So You Want to Be a Consultant? (S16-3) Careers
BioMarin San Rafael, CA
biomarin.com Biotech companies Biotech company developing and marketing treatments for rare genetic diseases, including enzyme replacement therapies.	Session Wed Nov 18 2:00pm–3:15pm The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Careers · with Bristol Myers Squibb 2:00pmConventional and Unconventional Trajectories to a Toxicologist Career in the Pharmaceutical Sector (S16-1)Boehringer Ingelheim 2:20pmTransitioning from Government Regulator to the Private Sector (S16-2)BlueRock Therapeutics 2:40pmSo You Want to Be a Consultant? (S16-3)Biologics Consulting
BlueRock Therapeutics
bluerocktx.com Biotech companies Clinical-stage cell therapy developer owned by Bayer, building cell replacement treatments for neurological and eye diseases.	Talk Wed Nov 18 2:20pm–2:40pm Part of The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Transitioning from Government Regulator to the Private Sector (S16-2) Careers

Instantly find 20 buyers in careers

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction

Instantly find 20 buyers in careers

Browse ACT 2026 by